• Global B-cell NHL market set to reach $9.2bn by 2027 biospectrumasia
    July 17, 2019
    CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients
PharmaSources Customer Service